pemvidutide
Selected indexed studies
- Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study. (J Hepatol, 2025) [PMID:39002641]
- Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study. (Lancet, 2025) [PMID:41237796]
- Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities. (Peptides, 2025) [PMID:40081498]
_Worker-drafted node — pending editorial review._
Connections
pemvidutide is a side effect of
Sources
- Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study. (2025) pubmed
- Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study. (2025) pubmed
- Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities. (2025) pubmed
- The dual GLP-1-glucagon agonist pemvidutide in MASH: a phase 2b trial. (2025) pubmed
- Safety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease: A randomized, controlled clinical trial. (2025) pubmed
- Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article. (2024) pubmed
- Muscle Loss in Obesity Therapy as a Therapeutic Target: Trial Design and Endpoints for Regulatory Discussions. (2025) pubmed
- Glucagon-like peptide 1 receptor agonists in substance use disorders: A systematic review of ClinicalTrials.Gov. (2026) pubmed
- Review: Special Issue: Real-world evidence on the use of GLP1 receptor agonists: Emerging concepts in obesity management: focus on glucagon receptor agonist combinations. (2025) pubmed
- Systemic Pharmacokinetic Principles of Therapeutic Peptides. (2026) pubmed